Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2, 3, and 4 Months Primary Schedule in Healthy Turkish Infants

NCT00315055 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT00315055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00315055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2, 3, and 4 Months Primary Schedule in Healthy Turkish Infants
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
February 29, 2008
Enrollment
310 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, hepatitis b, pertussis, polio